Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lighthouse II trial of Triumeq in amyotrophic lateral sclerosis
ISRCTN88446415Phase 3Completed
- Sponsor
- King's College London
- Start
- Jan 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, triple-blind trial in amyotrophic lateral sclerosis (ALS) comparing Triumeq plus standard care with Matched placebo plus standard care (2 arms). Primary endpoint: Overall survival. Started Jan 2022; status: completed.
02
Drugs
abacavir
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on ISRCTN88446415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN88446415.